1779. Trends in Anaplasmosis Over the Past Decade: A Review of Clinical Features, Laboratory Data and Outcomes Article Swipe
Silpita Katragadda
,
Zachary A. Yetmar
,
Supavit Chesdachai
,
Nischal Ranganath
,
Jonathan Wilcock
,
Omar Abu Saleh
,
Douglas W. Challener
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1093/ofid/ofad500.1608
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1093/ofid/ofad500.1608
Background Human granulocytic anaplasmosis (HGA) is an emerging tick-borne illness endemic to the northeastern and midwestern United States. Risk factors for the severity of infection, predictors for hospitalization, temporal trends, co-infections, and outcomes are poorly studied. Methods We conducted a retrospective review of HGA at Mayo Clinic, Rochester, between 2011-2021. Cases were identified by positive Anaplasma PCR at our reference laboratory. Variables included patients’ characteristics, symptoms, risk factors for tick-borne illness, laboratory parameters, co-infections, treatment, and clinical outcomes. Results We identified 471 cases with a positive Anaplasma PCR, and 146 cases were included in this interim analysis. Table 1 shows a summary of the baseline characteristics. An increasing annual trend in diagnosis of HGA was noted from 2014 to 2016 with lower rates observed during COVID-19 pandemic (2020 to 2022) (Figure 1). Of the 146 patients, 19 (13%) were immunocompromised secondary to hematologic malignancies, solid organ malignancies, and pharmacological immunosuppression. Frequently reported symptoms included fever (79.5%), malaise (68.5%), chills (51.4%), and myalgia (50%). Tick exposure was documented in 79.2 % of cases. Forty-seven (33%) patients were hospitalized; older patients were more likely to be hospitalized (Table 2). The most common complications among the hospitalized patients included respiratory failure (50%), encephalopathy (44.4%) and renal failure (37.5%). One patient required ICU admission. Twenty-five patients (17.5%) and one patient (0.7%) were co-infected with Lyme and Ehrlichiosis, respectively. Higher rates of leukopenia and thrombocytopenia were associated with mono-infection with Anaplasma (p < 0.001). Follow up data was available for 136 patients; all of them had favorable response to doxycycline.Table 1:Summary of baseline characteristics, labs and treatment.Table 2:Predictors of HospitalizationFigure 1:Annual Trends in Anaplasmosis from 2011-2021. Conclusion Our study demonstrated comprehensive clinical characteristics of patients with HGA. Interestingly, tick exposure history was common, yet most patients did not have other tick-borne co-infections. Furthermore, only a minority of patients developed severe diseases and required hospitalization. The recent decline in cases during the early part of the COVID-19 pandemic is worth further investigation. Disclosures All Authors: No reported disclosures
Related Topics
Concepts
Metadata
- Type
- review
- Language
- en
- Landing Page
- https://doi.org/10.1093/ofid/ofad500.1608
- https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.1608/53758505/ofad500.1608.pdf
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4389030346
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4389030346Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/ofid/ofad500.1608Digital Object Identifier
- Title
-
1779. Trends in Anaplasmosis Over the Past Decade: A Review of Clinical Features, Laboratory Data and OutcomesWork title
- Type
-
reviewOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-11-27Full publication date if available
- Authors
-
Silpita Katragadda, Zachary A. Yetmar, Supavit Chesdachai, Nischal Ranganath, Jonathan Wilcock, Omar Abu Saleh, Douglas W. ChallenerList of authors in order
- Landing page
-
https://doi.org/10.1093/ofid/ofad500.1608Publisher landing page
- PDF URL
-
https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.1608/53758505/ofad500.1608.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.1608/53758505/ofad500.1608.pdfDirect OA link when available
- Concepts
-
Medicine, myalgia, Ehrlichiosis, Chills, Anaplasmosis, Internal medicine, Leukopenia, Lymphocytopenia, Retrospective cohort study, Pediatrics, Alemtuzumab, Tick-borne disease, Tick, Transplantation, Lymphocyte, Virology, ChemotherapyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4389030346 |
|---|---|
| doi | https://doi.org/10.1093/ofid/ofad500.1608 |
| ids.doi | https://doi.org/10.1093/ofid/ofad500.1608 |
| ids.openalex | https://openalex.org/W4389030346 |
| fwci | 0.0 |
| type | review |
| title | 1779. Trends in Anaplasmosis Over the Past Decade: A Review of Clinical Features, Laboratory Data and Outcomes |
| biblio.issue | Supplement_2 |
| biblio.volume | 10 |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10296 |
| topics[0].field.id | https://openalex.org/fields/24 |
| topics[0].field.display_name | Immunology and Microbiology |
| topics[0].score | 0.9954000115394592 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2405 |
| topics[0].subfield.display_name | Parasitology |
| topics[0].display_name | Vector-borne infectious diseases |
| topics[1].id | https://openalex.org/T12047 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9937000274658203 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2725 |
| topics[1].subfield.display_name | Infectious Diseases |
| topics[1].display_name | Viral Infections and Vectors |
| topics[2].id | https://openalex.org/T10166 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.993399977684021 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2739 |
| topics[2].subfield.display_name | Public Health, Environmental and Occupational Health |
| topics[2].display_name | Mosquito-borne diseases and control |
| is_xpac | False |
| apc_list.value | 3064 |
| apc_list.currency | USD |
| apc_list.value_usd | 3064 |
| apc_paid.value | 3064 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 3064 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9122143387794495 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2778616394 |
| concepts[1].level | 2 |
| concepts[1].score | 0.7448269128799438 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q474959 |
| concepts[1].display_name | myalgia |
| concepts[2].id | https://openalex.org/C2778101375 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6676169633865356 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q2845432 |
| concepts[2].display_name | Ehrlichiosis |
| concepts[3].id | https://openalex.org/C2778594517 |
| concepts[3].level | 2 |
| concepts[3].score | 0.6459000706672668 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q2260058 |
| concepts[3].display_name | Chills |
| concepts[4].id | https://openalex.org/C2781329793 |
| concepts[4].level | 3 |
| concepts[4].score | 0.6244082450866699 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q2394735 |
| concepts[4].display_name | Anaplasmosis |
| concepts[5].id | https://openalex.org/C126322002 |
| concepts[5].level | 1 |
| concepts[5].score | 0.5486061573028564 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[5].display_name | Internal medicine |
| concepts[6].id | https://openalex.org/C2780873365 |
| concepts[6].level | 3 |
| concepts[6].score | 0.5282156467437744 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q496812 |
| concepts[6].display_name | Leukopenia |
| concepts[7].id | https://openalex.org/C2777990475 |
| concepts[7].level | 3 |
| concepts[7].score | 0.4970298111438751 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q485831 |
| concepts[7].display_name | Lymphocytopenia |
| concepts[8].id | https://openalex.org/C167135981 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4516526758670807 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q2146302 |
| concepts[8].display_name | Retrospective cohort study |
| concepts[9].id | https://openalex.org/C187212893 |
| concepts[9].level | 1 |
| concepts[9].score | 0.42602330446243286 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q123028 |
| concepts[9].display_name | Pediatrics |
| concepts[10].id | https://openalex.org/C2779015954 |
| concepts[10].level | 3 |
| concepts[10].score | 0.4219376742839813 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q420164 |
| concepts[10].display_name | Alemtuzumab |
| concepts[11].id | https://openalex.org/C2776005033 |
| concepts[11].level | 3 |
| concepts[11].score | 0.4174855351448059 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q184243 |
| concepts[11].display_name | Tick-borne disease |
| concepts[12].id | https://openalex.org/C2779620486 |
| concepts[12].level | 2 |
| concepts[12].score | 0.3419041037559509 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q10304508 |
| concepts[12].display_name | Tick |
| concepts[13].id | https://openalex.org/C2911091166 |
| concepts[13].level | 2 |
| concepts[13].score | 0.11482381820678711 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q106419912 |
| concepts[13].display_name | Transplantation |
| concepts[14].id | https://openalex.org/C2777761686 |
| concepts[14].level | 2 |
| concepts[14].score | 0.11211669445037842 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q715347 |
| concepts[14].display_name | Lymphocyte |
| concepts[15].id | https://openalex.org/C159047783 |
| concepts[15].level | 1 |
| concepts[15].score | 0.10710415244102478 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q7215 |
| concepts[15].display_name | Virology |
| concepts[16].id | https://openalex.org/C2776694085 |
| concepts[16].level | 2 |
| concepts[16].score | 0.0 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[16].display_name | Chemotherapy |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9122143387794495 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/myalgia |
| keywords[1].score | 0.7448269128799438 |
| keywords[1].display_name | myalgia |
| keywords[2].id | https://openalex.org/keywords/ehrlichiosis |
| keywords[2].score | 0.6676169633865356 |
| keywords[2].display_name | Ehrlichiosis |
| keywords[3].id | https://openalex.org/keywords/chills |
| keywords[3].score | 0.6459000706672668 |
| keywords[3].display_name | Chills |
| keywords[4].id | https://openalex.org/keywords/anaplasmosis |
| keywords[4].score | 0.6244082450866699 |
| keywords[4].display_name | Anaplasmosis |
| keywords[5].id | https://openalex.org/keywords/internal-medicine |
| keywords[5].score | 0.5486061573028564 |
| keywords[5].display_name | Internal medicine |
| keywords[6].id | https://openalex.org/keywords/leukopenia |
| keywords[6].score | 0.5282156467437744 |
| keywords[6].display_name | Leukopenia |
| keywords[7].id | https://openalex.org/keywords/lymphocytopenia |
| keywords[7].score | 0.4970298111438751 |
| keywords[7].display_name | Lymphocytopenia |
| keywords[8].id | https://openalex.org/keywords/retrospective-cohort-study |
| keywords[8].score | 0.4516526758670807 |
| keywords[8].display_name | Retrospective cohort study |
| keywords[9].id | https://openalex.org/keywords/pediatrics |
| keywords[9].score | 0.42602330446243286 |
| keywords[9].display_name | Pediatrics |
| keywords[10].id | https://openalex.org/keywords/alemtuzumab |
| keywords[10].score | 0.4219376742839813 |
| keywords[10].display_name | Alemtuzumab |
| keywords[11].id | https://openalex.org/keywords/tick-borne-disease |
| keywords[11].score | 0.4174855351448059 |
| keywords[11].display_name | Tick-borne disease |
| keywords[12].id | https://openalex.org/keywords/tick |
| keywords[12].score | 0.3419041037559509 |
| keywords[12].display_name | Tick |
| keywords[13].id | https://openalex.org/keywords/transplantation |
| keywords[13].score | 0.11482381820678711 |
| keywords[13].display_name | Transplantation |
| keywords[14].id | https://openalex.org/keywords/lymphocyte |
| keywords[14].score | 0.11211669445037842 |
| keywords[14].display_name | Lymphocyte |
| keywords[15].id | https://openalex.org/keywords/virology |
| keywords[15].score | 0.10710415244102478 |
| keywords[15].display_name | Virology |
| language | en |
| locations[0].id | doi:10.1093/ofid/ofad500.1608 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2735126445 |
| locations[0].source.issn | 2328-8957 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2328-8957 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Open Forum Infectious Diseases |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| locations[0].source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.1608/53758505/ofad500.1608.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Open Forum Infectious Diseases |
| locations[0].landing_page_url | https://doi.org/10.1093/ofid/ofad500.1608 |
| locations[1].id | pmh:oai:pubmedcentral.nih.gov:10677027 |
| locations[1].is_oa | True |
| locations[1].source.id | https://openalex.org/S2764455111 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed Central |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | cc-by |
| locations[1].pdf_url | https://pmc.ncbi.nlm.nih.gov/articles/PMC10677027/pdf/ofad500.1608.pdf |
| locations[1].version | submittedVersion |
| locations[1].raw_type | Text |
| locations[1].license_id | https://openalex.org/licenses/cc-by |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | Open Forum Infect Dis |
| locations[1].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/10677027 |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5011407774 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-2065-2586 |
| authorships[0].author.display_name | Silpita Katragadda |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I1330342723 |
| authorships[0].affiliations[0].raw_affiliation_string | Mayo clinic , Rochester, Rochester, Minnesota |
| authorships[0].institutions[0].id | https://openalex.org/I1330342723 |
| authorships[0].institutions[0].ror | https://ror.org/02qp3tb03 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I1330342723 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Mayo Clinic |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Silpita Katragadda |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Mayo clinic , Rochester, Rochester, Minnesota |
| authorships[1].author.id | https://openalex.org/A5024966479 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-2098-2868 |
| authorships[1].author.display_name | Zachary A. Yetmar |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I1330342723 |
| authorships[1].affiliations[0].raw_affiliation_string | Mayo Clinic , Rochester, Minnesota |
| authorships[1].institutions[0].id | https://openalex.org/I1330342723 |
| authorships[1].institutions[0].ror | https://ror.org/02qp3tb03 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I1330342723 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Mayo Clinic |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Zachary A Yetmar |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Mayo Clinic , Rochester, Minnesota |
| authorships[2].author.id | https://openalex.org/A5088301540 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-3507-6411 |
| authorships[2].author.display_name | Supavit Chesdachai |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I1330342723 |
| authorships[2].affiliations[0].raw_affiliation_string | Mayo Clinic , Rochester, Minnesota |
| authorships[2].institutions[0].id | https://openalex.org/I1330342723 |
| authorships[2].institutions[0].ror | https://ror.org/02qp3tb03 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I1330342723 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Mayo Clinic |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Supavit Chesdachai |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Mayo Clinic , Rochester, Minnesota |
| authorships[3].author.id | https://openalex.org/A5049492804 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-9538-6214 |
| authorships[3].author.display_name | Nischal Ranganath |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I1330342723 |
| authorships[3].affiliations[0].raw_affiliation_string | Mayo Clinic , Rochester, Minnesota |
| authorships[3].institutions[0].id | https://openalex.org/I1330342723 |
| authorships[3].institutions[0].ror | https://ror.org/02qp3tb03 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I1330342723 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Mayo Clinic |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Nischal Ranganath |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Mayo Clinic , Rochester, Minnesota |
| authorships[4].author.id | https://openalex.org/A5027044104 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-4315-2536 |
| authorships[4].author.display_name | Jonathan Wilcock |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I1330342723 |
| authorships[4].affiliations[0].raw_affiliation_string | Mayo Clinic , Rochester, Minnesota |
| authorships[4].institutions[0].id | https://openalex.org/I1330342723 |
| authorships[4].institutions[0].ror | https://ror.org/02qp3tb03 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I1330342723 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Mayo Clinic |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Jonathan Wilcock |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Mayo Clinic , Rochester, Minnesota |
| authorships[5].author.id | https://openalex.org/A5081951764 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-4955-5544 |
| authorships[5].author.display_name | Omar Abu Saleh |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I1330342723 |
| authorships[5].affiliations[0].raw_affiliation_string | Mayo Clinic Rochester , Rochester, Minnesota |
| authorships[5].institutions[0].id | https://openalex.org/I1330342723 |
| authorships[5].institutions[0].ror | https://ror.org/02qp3tb03 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I1330342723 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Mayo Clinic |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Omar M Abu Saleh |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Mayo Clinic Rochester , Rochester, Minnesota |
| authorships[6].author.id | https://openalex.org/A5076147784 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-6964-9639 |
| authorships[6].author.display_name | Douglas W. Challener |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I1330342723 |
| authorships[6].affiliations[0].raw_affiliation_string | Mayo Clinic , Rochester, Minnesota |
| authorships[6].institutions[0].id | https://openalex.org/I1330342723 |
| authorships[6].institutions[0].ror | https://ror.org/02qp3tb03 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I1330342723 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Mayo Clinic |
| authorships[6].author_position | last |
| authorships[6].raw_author_name | Douglas Challener |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Mayo Clinic , Rochester, Minnesota |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.1608/53758505/ofad500.1608.pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | 1779. Trends in Anaplasmosis Over the Past Decade: A Review of Clinical Features, Laboratory Data and Outcomes |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10296 |
| primary_topic.field.id | https://openalex.org/fields/24 |
| primary_topic.field.display_name | Immunology and Microbiology |
| primary_topic.score | 0.9954000115394592 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2405 |
| primary_topic.subfield.display_name | Parasitology |
| primary_topic.display_name | Vector-borne infectious diseases |
| related_works | https://openalex.org/W4308345274, https://openalex.org/W2144268650, https://openalex.org/W4301359999, https://openalex.org/W2162879800, https://openalex.org/W2956043083, https://openalex.org/W2462527331, https://openalex.org/W4318912359, https://openalex.org/W2414538452, https://openalex.org/W4211021767, https://openalex.org/W1556366816 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1093/ofid/ofad500.1608 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2735126445 |
| best_oa_location.source.issn | 2328-8957 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2328-8957 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Open Forum Infectious Diseases |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| best_oa_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.1608/53758505/ofad500.1608.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Open Forum Infectious Diseases |
| best_oa_location.landing_page_url | https://doi.org/10.1093/ofid/ofad500.1608 |
| primary_location.id | doi:10.1093/ofid/ofad500.1608 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2735126445 |
| primary_location.source.issn | 2328-8957 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2328-8957 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Open Forum Infectious Diseases |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| primary_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.1608/53758505/ofad500.1608.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Open Forum Infectious Diseases |
| primary_location.landing_page_url | https://doi.org/10.1093/ofid/ofad500.1608 |
| publication_date | 2023-11-27 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.% | 170 |
| abstract_inverted_index.1 | 99 |
| abstract_inverted_index.a | 40, 85, 101, 300 |
| abstract_inverted_index.(p | 237 |
| abstract_inverted_index.19 | 137 |
| abstract_inverted_index.An | 107 |
| abstract_inverted_index.No | 330 |
| abstract_inverted_index.Of | 133 |
| abstract_inverted_index.We | 38, 80 |
| abstract_inverted_index.an | 7 |
| abstract_inverted_index.at | 45, 58 |
| abstract_inverted_index.be | 184 |
| abstract_inverted_index.by | 54 |
| abstract_inverted_index.in | 94, 111, 168, 268, 313 |
| abstract_inverted_index.is | 6, 323 |
| abstract_inverted_index.of | 24, 43, 103, 113, 171, 227, 249, 257, 264, 279, 302, 319 |
| abstract_inverted_index.to | 12, 119, 129, 142, 183, 254 |
| abstract_inverted_index.up | 241 |
| abstract_inverted_index.1). | 132 |
| abstract_inverted_index.136 | 246 |
| abstract_inverted_index.146 | 90, 135 |
| abstract_inverted_index.2). | 187 |
| abstract_inverted_index.471 | 82 |
| abstract_inverted_index.All | 328 |
| abstract_inverted_index.HGA | 44, 114 |
| abstract_inverted_index.ICU | 209 |
| abstract_inverted_index.One | 206 |
| abstract_inverted_index.Our | 273 |
| abstract_inverted_index.PCR | 57 |
| abstract_inverted_index.The | 188, 310 |
| abstract_inverted_index.all | 248 |
| abstract_inverted_index.and | 15, 32, 76, 89, 148, 161, 202, 214, 222, 229, 261, 307 |
| abstract_inverted_index.are | 34 |
| abstract_inverted_index.did | 292 |
| abstract_inverted_index.for | 21, 27, 69, 245 |
| abstract_inverted_index.had | 251 |
| abstract_inverted_index.not | 293 |
| abstract_inverted_index.one | 215 |
| abstract_inverted_index.our | 59 |
| abstract_inverted_index.the | 13, 22, 104, 134, 193, 316, 320 |
| abstract_inverted_index.was | 115, 166, 243, 287 |
| abstract_inverted_index.yet | 289 |
| abstract_inverted_index.2014 | 118 |
| abstract_inverted_index.2016 | 120 |
| abstract_inverted_index.79.2 | 169 |
| abstract_inverted_index.HGA. | 282 |
| abstract_inverted_index.Lyme | 221 |
| abstract_inverted_index.Mayo | 46 |
| abstract_inverted_index.PCR, | 88 |
| abstract_inverted_index.Risk | 19 |
| abstract_inverted_index.Tick | 164 |
| abstract_inverted_index.data | 242 |
| abstract_inverted_index.from | 117, 270 |
| abstract_inverted_index.have | 294 |
| abstract_inverted_index.labs | 260 |
| abstract_inverted_index.more | 181 |
| abstract_inverted_index.most | 189, 290 |
| abstract_inverted_index.only | 299 |
| abstract_inverted_index.part | 318 |
| abstract_inverted_index.risk | 67 |
| abstract_inverted_index.them | 250 |
| abstract_inverted_index.this | 95 |
| abstract_inverted_index.tick | 284 |
| abstract_inverted_index.were | 52, 92, 139, 176, 180, 218, 231 |
| abstract_inverted_index.with | 84, 121, 220, 233, 235, 281 |
| abstract_inverted_index.(13%) | 138 |
| abstract_inverted_index.(2020 | 128 |
| abstract_inverted_index.(33%) | 174 |
| abstract_inverted_index.(HGA) | 5 |
| abstract_inverted_index.2022) | 130 |
| abstract_inverted_index.Cases | 51 |
| abstract_inverted_index.Human | 2 |
| abstract_inverted_index.Table | 98 |
| abstract_inverted_index.among | 192 |
| abstract_inverted_index.cases | 83, 91, 314 |
| abstract_inverted_index.early | 317 |
| abstract_inverted_index.fever | 155 |
| abstract_inverted_index.lower | 122 |
| abstract_inverted_index.noted | 116 |
| abstract_inverted_index.older | 178 |
| abstract_inverted_index.organ | 146 |
| abstract_inverted_index.other | 295 |
| abstract_inverted_index.rates | 123, 226 |
| abstract_inverted_index.renal | 203 |
| abstract_inverted_index.shows | 100 |
| abstract_inverted_index.solid | 145 |
| abstract_inverted_index.study | 274 |
| abstract_inverted_index.trend | 110 |
| abstract_inverted_index.worth | 324 |
| abstract_inverted_index.(0.7%) | 217 |
| abstract_inverted_index.(50%), | 199 |
| abstract_inverted_index.(50%). | 163 |
| abstract_inverted_index.(Table | 186 |
| abstract_inverted_index.Follow | 240 |
| abstract_inverted_index.Higher | 225 |
| abstract_inverted_index.Trends | 267 |
| abstract_inverted_index.United | 17 |
| abstract_inverted_index.annual | 109 |
| abstract_inverted_index.cases. | 172 |
| abstract_inverted_index.chills | 159 |
| abstract_inverted_index.common | 190 |
| abstract_inverted_index.during | 125, 315 |
| abstract_inverted_index.likely | 182 |
| abstract_inverted_index.poorly | 35 |
| abstract_inverted_index.recent | 311 |
| abstract_inverted_index.review | 42 |
| abstract_inverted_index.severe | 305 |
| abstract_inverted_index.(17.5%) | 213 |
| abstract_inverted_index.(44.4%) | 201 |
| abstract_inverted_index.(Figure | 131 |
| abstract_inverted_index.0.001). | 239 |
| abstract_inverted_index.Clinic, | 47 |
| abstract_inverted_index.Methods | 37 |
| abstract_inverted_index.Results | 79 |
| abstract_inverted_index.States. | 18 |
| abstract_inverted_index.between | 49 |
| abstract_inverted_index.common, | 288 |
| abstract_inverted_index.decline | 312 |
| abstract_inverted_index.endemic | 11 |
| abstract_inverted_index.factors | 20, 68 |
| abstract_inverted_index.failure | 198, 204 |
| abstract_inverted_index.further | 325 |
| abstract_inverted_index.history | 286 |
| abstract_inverted_index.illness | 10 |
| abstract_inverted_index.interim | 96 |
| abstract_inverted_index.malaise | 157 |
| abstract_inverted_index.myalgia | 162 |
| abstract_inverted_index.patient | 207, 216 |
| abstract_inverted_index.summary | 102 |
| abstract_inverted_index.trends, | 30 |
| abstract_inverted_index.&lt; | 238 |
| abstract_inverted_index.(37.5%). | 205 |
| abstract_inverted_index.(51.4%), | 160 |
| abstract_inverted_index.(68.5%), | 158 |
| abstract_inverted_index.(79.5%), | 156 |
| abstract_inverted_index.1:Annual | 266 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Authors: | 329 |
| abstract_inverted_index.COVID-19 | 126, 321 |
| abstract_inverted_index.baseline | 105, 258 |
| abstract_inverted_index.clinical | 77, 277 |
| abstract_inverted_index.diseases | 306 |
| abstract_inverted_index.emerging | 8 |
| abstract_inverted_index.exposure | 165, 285 |
| abstract_inverted_index.illness, | 71 |
| abstract_inverted_index.included | 63, 93, 154, 196 |
| abstract_inverted_index.minority | 301 |
| abstract_inverted_index.observed | 124 |
| abstract_inverted_index.outcomes | 33 |
| abstract_inverted_index.pandemic | 127, 322 |
| abstract_inverted_index.patients | 175, 179, 195, 212, 280, 291, 303 |
| abstract_inverted_index.positive | 55, 86 |
| abstract_inverted_index.reported | 152, 331 |
| abstract_inverted_index.required | 208, 308 |
| abstract_inverted_index.response | 253 |
| abstract_inverted_index.severity | 23 |
| abstract_inverted_index.studied. | 36 |
| abstract_inverted_index.symptoms | 153 |
| abstract_inverted_index.temporal | 29 |
| abstract_inverted_index.1:Summary | 256 |
| abstract_inverted_index.Anaplasma | 56, 87, 236 |
| abstract_inverted_index.Variables | 62 |
| abstract_inverted_index.analysis. | 97 |
| abstract_inverted_index.available | 244 |
| abstract_inverted_index.conducted | 39 |
| abstract_inverted_index.developed | 304 |
| abstract_inverted_index.diagnosis | 112 |
| abstract_inverted_index.favorable | 252 |
| abstract_inverted_index.outcomes. | 78 |
| abstract_inverted_index.patients, | 136 |
| abstract_inverted_index.patients; | 247 |
| abstract_inverted_index.reference | 60 |
| abstract_inverted_index.secondary | 141 |
| abstract_inverted_index.symptoms, | 66 |
| abstract_inverted_index.2011-2021. | 50, 271 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Conclusion | 272 |
| abstract_inverted_index.Frequently | 151 |
| abstract_inverted_index.Rochester, | 48 |
| abstract_inverted_index.admission. | 210 |
| abstract_inverted_index.associated | 232 |
| abstract_inverted_index.documented | 167 |
| abstract_inverted_index.identified | 53, 81 |
| abstract_inverted_index.increasing | 108 |
| abstract_inverted_index.infection, | 25 |
| abstract_inverted_index.laboratory | 72 |
| abstract_inverted_index.leukopenia | 228 |
| abstract_inverted_index.midwestern | 16 |
| abstract_inverted_index.predictors | 26 |
| abstract_inverted_index.tick-borne | 9, 70, 296 |
| abstract_inverted_index.treatment, | 75 |
| abstract_inverted_index.Disclosures | 327 |
| abstract_inverted_index.Forty-seven | 173 |
| abstract_inverted_index.Twenty-five | 211 |
| abstract_inverted_index.co-infected | 219 |
| abstract_inverted_index.disclosures | 332 |
| abstract_inverted_index.hematologic | 143 |
| abstract_inverted_index.laboratory. | 61 |
| abstract_inverted_index.parameters, | 73 |
| abstract_inverted_index.patients’ | 64 |
| abstract_inverted_index.respiratory | 197 |
| abstract_inverted_index.2:Predictors | 263 |
| abstract_inverted_index.Anaplasmosis | 269 |
| abstract_inverted_index.Furthermore, | 298 |
| abstract_inverted_index.anaplasmosis | 4 |
| abstract_inverted_index.demonstrated | 275 |
| abstract_inverted_index.granulocytic | 3 |
| abstract_inverted_index.hospitalized | 185, 194 |
| abstract_inverted_index.northeastern | 14 |
| abstract_inverted_index.Ehrlichiosis, | 223 |
| abstract_inverted_index.complications | 191 |
| abstract_inverted_index.comprehensive | 276 |
| abstract_inverted_index.hospitalized; | 177 |
| abstract_inverted_index.malignancies, | 144, 147 |
| abstract_inverted_index.respectively. | 224 |
| abstract_inverted_index.retrospective | 41 |
| abstract_inverted_index.Interestingly, | 283 |
| abstract_inverted_index.co-infections, | 31, 74 |
| abstract_inverted_index.co-infections. | 297 |
| abstract_inverted_index.encephalopathy | 200 |
| abstract_inverted_index.investigation. | 326 |
| abstract_inverted_index.mono-infection | 234 |
| abstract_inverted_index.characteristics | 278 |
| abstract_inverted_index.pharmacological | 149 |
| abstract_inverted_index.treatment.Table | 262 |
| abstract_inverted_index.characteristics, | 65, 259 |
| abstract_inverted_index.characteristics. | 106 |
| abstract_inverted_index.hospitalization, | 28 |
| abstract_inverted_index.hospitalization. | 309 |
| abstract_inverted_index.thrombocytopenia | 230 |
| abstract_inverted_index.doxycycline.Table | 255 |
| abstract_inverted_index.immunocompromised | 140 |
| abstract_inverted_index.immunosuppression. | 150 |
| abstract_inverted_index.HospitalizationFigure | 265 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 7 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8600000143051147 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.18295718 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |